Trial Profile
A Phase IV Study of Nilotinib in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Who Have Suboptimal Molecular Response on Imatinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms SENSOR
- Sponsors Novartis Pharmaceuticals
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.
- 16 Jan 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
- 10 Dec 2013 Interim results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.